



ALS/MND Science Day – Scientific Program

Thursday, 12Oct2023		
18:30 - 20:00		Dinner – meet and greet
20:00	M. Cudkowicz	Keynote Lecture Update on Clinical Trials and Therapeutics in US
Friday, 13Oct2023		
09:00	A. C. Ludolph	Opening ALS/MND Science Day
09:15 - 10:45		Young Forum I – basic science Chair: S. Petri, A. Hermann
	M. Naumann, Rostock	Contribution of innate immune signaling pathways to FUS-ALS pathology
	L. Tzeplaeff, München	The PREMODIALS Project, Identification of a disease signature for presymptomatic and early ALS
	M. Dohrn, Aachen	Novel <i>de-novo</i> mutation dysregulates sphingolipid production and links <i>SPTLC2</i> with juvenile-onset amyotrophic lateral sclerosis
	A.Ponomarenko, Ulm	Deciphering amyotrophic lateral sclerosis linked to <i>NEK1</i> mutations
	P. Schumann, Berlin	Frequency of SOD1 and FUS mutations in a multicenter screening program in Germany – implication for early access program and clinical trial enrollment
	V. Klose, Ulm	CSF Data Digitalization and Analysis of 1059 ALS Patients
10:45 - 11:15		Coffee break – get together
11:15 - 13:00		Young Forum II – clinical and translational research Chair: M. Cudkowicz, A.C. Ludolph
	A. German, Erlangen	The Brain Archive: A New Perspective for the Care of Palliative Patients
	S. Castro-Gomez	cTnT and CK-MB are supportive biomarkers in the diagnosis and follow-up of ALS
	D. Brenner, Ulm	Phenotypes of ALS patients with mutations in the genes <i>NEK1</i> and <i>TBK1</i>
	A. Maier, Berlin	Clinical use and comparative analysis of the self-explanatory ALS functional rating scale (ALSF _{RS} -R-SE)
	A. Lehto, Rostock	Association between cognitive performance, glucose metabolism, and grey matter volume in ALS





	M. Monti, Berlin	Self-reported and prioritized symptoms and impairments in ALS – result from a large multicenter study
	S. Witzel, Ulm	Serum neurofilament data from the ALS Registry Swabia support the utility as a surrogate marker for survival and disease progression
13:00 - 14:00		Lunch – get together
14:00 - 15:00		Young Forum III – clinical studies and IITs Chair: T. Meyer, J. Grosskreutz
	C. Hermann, Ulm	Ketogenic diet in ALS - a potential treatment option?
	J. Conrad, Mannheim	Quantitative susceptibility mapping in the course of disease in ALS – a planned multicenter study
	P.Körtvélyessy, Berlin	Clinical and neurofilament light-chain response to tofersen in SOD1-ALS: results of a multicenter observational study
	M. Wiesenfahrt, Ulm	12-month data from Tofersen-EAP in the German MND-network
15:00 - 15:30		Young Forum IV – SMA Chair: T. Hagenacker, S. Witzel
	S. Brakemeier, Essen	NPTX2, a potential biomarker for Nusinersen therapy response in adults with SMA
	H. S. Lapp, Dresden	Muscle integrity markers as biomarkers in 5q-associated SMA“
15:30	A. C. Ludolph	Closing

